Outcomes N Summary estimate 95% CI
Current clinical control
Change from baseline in asthma control days
214 MD = -0.07 -0.14, -0.01
Proportion of asthma control days 330 MD = -0.09 -0.14, -0.04
Change from baseline use of β2-agonists (puffs/day) 442 MD = 0.12  0.00, 0.23
Cumulative doses of rescue albuterol (μg) 214 MD = 51.47 11.36, 91.57
Change from baseline morning PEFR (%) 350 MD = -2.56 -4.49, -0.63
Change from baseline in FEV1 (%) 365 MD = -0.49 -5.82, 4.84
Change from baseline in exhaled NO (parts per billion) 214 MD = 16.80 11.95, 21.64
Change from baseline in the proportion of symptom-free days 984 SMD = -0.15 -0.28, -0.03
Change from baseline in daytime symptom scores 591 SMD = 0.13 -0.04, 0.29
Change from baseline in night-time awakenings 448 MD = -0.03 -0.08, 0.02
Change from baseline in quality of life 389 SMD = -0.16 -0.36, 0.04
Future risk
Time to first exacerbation requiring oral corticosteroids
492 HR = 0.88  0.55, 1.40
Patients with ≥1 exacerbation requiring an acute care visit 1055 RR = 1.08  0.90, 1.30
Patients with  ≥1 exacerbation requiring  a hospital admission 1204 RR = 0.85  0.29, 2.49
Number of exacerbations requiring ED visits 264 RR = 0.69  0.14, 3.44
Overall withdrawals 1210 RR = 1.04  0.79, 1.37
Withdrawals due to poor asthma control 1063 RR = 1.60  0.56, 4.52
Withdrawals due to adverse effects 1063 RR = 0.78  0.21, 2.92
Overall adverse effects 726 RR = 1.00  0.89, 1.13
Nausea 393 RR = 1.15  0.56, 2.35
Upper respiratory tract infection 393 RR = 1.14  0.96, 1.35
Change in height (cm) 532 MD = 0.41  0.13, 0.69
MD: Mean Difference; SMD: Standard Mean Difference; HR: Hazard Ratio; RR: Risk Ratio; PEFR: Peak Expiratory Flow Rate; FEV1: Forced Expired Volume In One Second; NO: Nitric Oxide.
Table 2: Secondary outcomes.
Goto home»